183 related articles for article (PubMed ID: 33138841)
1. In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myeloma.
Omstead DT; Mejia F; Sjoerdsma J; Kim B; Shin J; Khan S; Wu J; Kiziltepe T; Littlepage LE; Bilgicer B
J Hematol Oncol; 2020 Nov; 13(1):145. PubMed ID: 33138841
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel-Fe3O4 nanoparticles inhibit growth of CD138(-) CD34(-) tumor stem-like cells in multiple myeloma-bearing mice.
Yang C; Wang J; Chen D; Chen J; Xiong F; Zhang H; Zhang Y; Gu N; Dou J
Int J Nanomedicine; 2013; 8():1439-49. PubMed ID: 23610522
[TBL] [Abstract][Full Text] [Related]
3. Liposomes targeted to MHC-restricted antigen improve drug delivery and antimelanoma response.
Saeed M; Zalba S; Seynhaeve ALB; Debets R; Ten Hagen TLM
Int J Nanomedicine; 2019; 14():2069-2089. PubMed ID: 30988609
[TBL] [Abstract][Full Text] [Related]
4. Liposomal drug delivery in an in vitro 3D bone marrow model for multiple myeloma.
Braham MV; Deshantri AK; Minnema MC; Öner FC; Schiffelers RM; Fens MH; Alblas J
Int J Nanomedicine; 2018; 13():8105-8118. PubMed ID: 30555229
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Development of Near-Infrared-Labeled CD38-Targeted Daratumumab for Optical Imaging of CD38 in Multiple Myeloma.
Cho N; Ko S; Shokeen M
Mol Imaging Biol; 2021 Apr; 23(2):186-195. PubMed ID: 32964391
[TBL] [Abstract][Full Text] [Related]
6. Liposomes for targeting hepatocellular carcinoma: use of conjugated arabinogalactan as targeting ligand.
Shah SM; Goel PN; Jain AS; Pathak PO; Padhye SG; Govindarajan S; Ghosh SS; Chaudhari PR; Gude RP; Gopal V; Nagarsenker MS
Int J Pharm; 2014 Dec; 477(1-2):128-39. PubMed ID: 25311181
[TBL] [Abstract][Full Text] [Related]
7. Optimizing design parameters of a peptide targeted liposomal nanoparticle in an in vivo multiple myeloma disease model after initial evaluation in vitro.
Stefanick JF; Omstead DT; Ashley JD; Deak PE; Mustafaoglu N; Kiziltepe T; Bilgicer B
J Control Release; 2019 Oct; 311-312():190-200. PubMed ID: 31473250
[TBL] [Abstract][Full Text] [Related]
8. Double CD38
Mykytiv V; Alwaheed A; Mohd Hashim NA
Hematol Oncol Stem Cell Ther; 2019 Mar; 12(1):64-66. PubMed ID: 29079129
[TBL] [Abstract][Full Text] [Related]
9. Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma.
Cengiz A; Arda HÜ; Döğer F; Yavaşoğlu İ; Yürekli Y; Bolaman AZ
Turk J Haematol; 2018 Aug; 35(3):175-180. PubMed ID: 29806594
[TBL] [Abstract][Full Text] [Related]
10. Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma.
de la Puente P; Luderer MJ; Federico C; Jin A; Gilson RC; Egbulefu C; Alhallak K; Shah S; Muz B; Sun J; King J; Kohnen D; Salama NN; Achilefu S; Vij R; Azab AK
J Control Release; 2018 Jan; 270():158-176. PubMed ID: 29196043
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Development of CD38-Targeted [
Ghai A; Maji D; Cho N; Chanswangphuwana C; Rettig M; Shen D; DiPersio J; Akers W; Dehdashti F; Achilefu S; Vij R; Shokeen M
J Nucl Med; 2018 Feb; 59(2):216-222. PubMed ID: 29025987
[TBL] [Abstract][Full Text] [Related]
12. Peptide PHSCNK as an integrin α5β1 antagonist targets stealth liposomes to integrin-overexpressing melanoma.
Dai W; Yang T; Wang Y; Wang X; Wang J; Zhang X; Zhang Q
Nanomedicine; 2012 Oct; 8(7):1152-61. PubMed ID: 22306158
[TBL] [Abstract][Full Text] [Related]
13. A specific peptide ligand-modified lipid nanoparticle carrier for the inhibition of tumor metastasis growth.
Wang Z; Yu Y; Dai W; Cui J; Wu H; Yuan L; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
Biomaterials; 2013 Jan; 34(3):756-64. PubMed ID: 23117217
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
Allen TM; Mumbengegwi DR; Charrois GJ
Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261
[TBL] [Abstract][Full Text] [Related]
15. CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells.
Kim D; Park CY; Medeiros BC; Weissman IL
Leukemia; 2012 Dec; 26(12):2530-7. PubMed ID: 22733078
[TBL] [Abstract][Full Text] [Related]
16. Tumor-targeted delivery of liposome-encapsulated doxorubicin by use of a peptide that selectively binds to irradiated tumors.
Lowery A; Onishko H; Hallahan DE; Han Z
J Control Release; 2011 Feb; 150(1):117-24. PubMed ID: 21075152
[TBL] [Abstract][Full Text] [Related]
17. Folate and TAT peptide co-modified liposomes exhibit receptor-dependent highly efficient intracellular transport of payload in vitro and in vivo.
Zhu Y; Cheng L; Cheng L; Huang F; Hu Q; Li L; Tian C; Wei L; Chen D
Pharm Res; 2014 Dec; 31(12):3289-303. PubMed ID: 24858397
[TBL] [Abstract][Full Text] [Related]
18.
Quelven I; Monteil J; Sage M; Saidi A; Mounier J; Bayout A; Garrier J; Cogne M; Durand-Panteix S
J Nucl Med; 2020 Jul; 61(7):1058-1065. PubMed ID: 31862796
[TBL] [Abstract][Full Text] [Related]
19. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region.
Amin M; Mansourian M; Koning GA; Badiee A; Jaafari MR; Ten Hagen TLM
J Control Release; 2015 Dec; 220(Pt A):308-315. PubMed ID: 26526970
[TBL] [Abstract][Full Text] [Related]
20. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv.
Cheng WW; Allen TM
J Control Release; 2008 Feb; 126(1):50-8. PubMed ID: 18068849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
